INTRODUCTION
As a classic method, linear discriminant analysis (LDA) has been well studied and widely used. It is well known for its simplicity as well as robustness. Suppose we have a class variable Y with possible values in G = {1, 2, · · · , K} and a real valued random input vector X, the optimal decision rule based on the 0-1 loss is the Bayes rule:Ŷ (X) = argmax k∈G P (Y = k|X = x). In the context of sample classifications with microarray gene expression data, Y represents one of K sample groups (e.g. tumors or normal tissues) * to whom correspondence should be addressed and X represents the gene expression profile of a patient. According to the Bayes theorem, we have P (Y = k|X = x) ∝ P (X = x|Y = k)P (G = k).
In LDA, X|Y = k is assumed to have a multivariate normal distribution M V N (µ k , Σ). By some simple calculations, we havê
is a linear discriminant function in x. Thus, the classification problem reduces to estimating the parameters in the distribution f (X|Y = k). Traditionally, the maximum likelihood estimators (MLEs) of µ k and Σ, the sample mean and sample covariance, are used:μ k = (μ 1k , . . . ,μ pk ) T ,μ ik = 1 n k X y j =k xij , realize variable selection. SCRDA was shown to slightly outperform PAM in some occasions. We feel that both PAM and SCRDA are at the ends of the two extremes: the covariance matrix in the former is restricted to be diagonal while in the latter there is barely any restriction. Based on the biology of gene functions, we aim to estimate the covariance matrix as an intermediate between the two. The idea is in line with recent efforts of integrating biological information of genes, as available in the Gene Ontology (GO) annotations (Ashburner et al 2000) , Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Kanehisa 1996) or constructed gene networks, into the process of model building. Several methods in this line have been proposed. Lottaz and Spang (2005) proposed a structured analysis of microarray data (StAM), while Wei and Li (2007) proposed a modified boosting method called nonparametric pathway-based regression (NPR). More recently, Tai and Pan (2007) proposed a group penalization method that handles the genes within different functional groups with different penalty terms. The common rationale behind all these methods is simple: many genes are known to have the same function or involved in the same pathway as that of some known/putative cancer-related genes, and the genes in the same functional group or pathway are more likely to work together. The methods aim to borrow information from existing biological knowledge to improve both predictive accuracy and interpretability of a resulting classifier.
In this paper, we propose several versions of a modified LDA, group regularized discriminant analysis (GRDA) that aims to take advantage of existing gene functional groups. Specifically, we lean on, but do not require, the assumption that the genes within the same group are correlated with each other, but are independent of the genes from other groups, leading to a block-diagonal covariance structure. In addition, rather than shrinking individually for each gene as in PAM and SCRDA, again by taking advantage of known gene groups, we propose a group shrinkage scheme to identify biologically significant gene functional groups or pathways.
The rest of the paper is organized as follows. We first review the PAM and SCRDA. Then we introduce our new methods GRDA with three combinations of choosing between two regularized covariance matrices and between two shrinkage schemes. We also discuss some computational issues such that an efficient implementation makes it feasible to handle very high-dimensional data. Results from simulation studies and analyses of four public cancer data sets are presented to evaluate the proposed methods, demonstrating their potential gains over PAM and SCRDA. We end with a short summary and discussion.
METHODS

PAM
The nearest shrunken centroids (PAM) method assumes the independence among the genes, ignoring any possible correlation among the genes. It uses a soft-thresholding rule to shrinkμ ik towards 0, thus eliminating noise genes. Suppose we have n samples and p genes. Let x ij be the expression level of gene i in sample j. To simplify the discussion, we assume that x ij 's across j have been centered at 0; that is,x i = P j x ij /n = 0 for all genes. The basic idea of PAM is to shrink the class centroids or class-specific sample meansx ik towards the overall centroidx i . Let
where s i is the pooled within-class standard deviation defined by
with s 0 being a positive constant, usually set as the median of {s i : i = 1, ..., p}, and m k = p 1/n k − 1/n. Basically, d ik is a modified t-statistic for gene i. We can rewritex ik = m k (s i + s 0 )d ik and shrink d ik towards zero by an amount λ ≥ 0 by soft thresholding:
where λ is a tuning parameter that has to be decided, usually by crossvalidation (CV). We thus obtain a new shrunken centroid
and define a discriminant score for class k as
is a new test sample and π k = n k /n is the estimated class prior probability. It is noted that, if the class centroidsx ik = 0 for all k, then gene i does not contribute to classification and is regarded as a noise gene.
SCRDA
Instead of completely ignoring the correlations between genes, the shrunken centroids regularized discriminant analysis (SCRDA) aims to estimate the covariance matrix in a general way:
whereΣ is the sample covariance matrix (i.e. MLE). It aims to adaptively find an optimal intermediate between the unstructured and the independence covariance structures. By regularization,Σ will typically be non-singular. Next, SCRDA shrinks the transformed class meanμ * k towards 0:
Finally, SCRDA transformsμ *
, and classifies a new samplex using discriminant score
One problem with SCRDA is that in fact it cannot realize gene selection, which has not been pointed out previously in the literature. The reason is the following. First, eachμ * ik is a linear combination ofμ ik 's. Second, if µ * ik(s) = 0 for k = 1, . . . , K, according to the decision rule, gene i in new samplex will not contribute to classification; however, it still contributes to constructing the decision rule since otherμ * jk (s) for j = i depends on gene i viaμ ik andΣ.
Group Regularized Discriminant Analysis (GRDA)
Many studies have shown that genes in the same functional group or involved in the same pathway are more likely to co-express, hence their expression levels tend to be correlated. In this paper, we aim to incorporate such biological information into the development of a regularized covariance matrix estimator and a grouped shrinkage scheme. In contrast, neither PAM nor SCRDA takes advantage of such biological information.
Regularized Covariance Matrix
Instead of shrinking the sample covariance matrix to an independence structure, we shrink it to a between-group independence structure:
where α 1 , α 2 and α 1 + α 2 ∈ [0, 1] are some tuning parameters to be determined; as a simpler alternative, we also consider using
whereΣ is the sample covariance matrix,D = diag(Σ) is a diagonal matrix with the sample variances as diagonal entries, andΣ * = diag(Σ 1 ,Σ 2 , · · · ,Σ G ) is block-diagonal withΣ i being a p i × p i sample covariance matrix for genes in group i. We call the resulting discriminant analysis with the regularized covariance estimate in (4) or (5) Group Regularized Discriminant Analysis (GRDA), and denote them as GRDA-1 and GRDA-2 respectively.
Shrunken Centroids GRDA (SCGRDA)
Next we consider two shrinkage schemes. The first one is exactly the same as in SCRDA; we call it individual shrinkage as opposed to the second one, called group shrinkage.
The first one works as follows,
k . As pointed out before, this shrinkage scheme with a non-diagonal covariance matrix cannot realize gene selection.
The second one is a group shrinkage that tends to retain or remove all the variables or genes in a group (Yuan and Lin 2006; Cai 1999) . Instead of shrinking eachμ * ik individually, we shrink them as a group. With regularized covariance matrix (5), which assumes between-group independence, we can actually perform gene selection at group level. Specifically,
lk is the L 2 norm and p j = |G j | is the group size. If ||μ * k || G j for group j is larger than the threshold λ √ p j , then all theμ * ik 's in group j are retained and only shrunken towards 0; otherwise, all theμ * ik in this group are shrunken to be exactly zero, not contributing to classification, thus realizing gene selection at a group level.
With the two choices of a regularized covariance matrix and two choices of a shrinkage scheme, we have three possible methods:
1. ISCGRDA-1: GRDA-1 with individual shrinkage; 2. ISCGRDA-2: GRDA-2 with individual shrinkage; 3. GSCGRDA: GRDA-2 with group shrinkage.
Tuning parameters
In GRDA-1, we have three tuning parameters whose values need to be determined by cross-validation (CV): α 1 , α 2 and λ, and two tuning parameters for GRDA-2: α and λ. We perform a grid search in a tuning parameter space. The grids for α 1 , α 2 or α range from 0 to 0.99 with a equally spaced grids and a was 10 in our study. The grids for λ conventionally range from 0 to the maximum of the absolute values of the parameter that needs to be shrunken; for example, in PAM, it ranges from 0 to max(|d k |). However, in SCRDA and our method SCGRDA,μ * k , the parameter that needs to be shrunken, depends onΣ, which changes with α. SCRDA fixes the range of λ to simplify the computation.
Instead of directly searching in grids of λ, we introduce another parameter θ, which is a proportion of the total number of genes or gene groups remaining in the model. The range of θ was fixed from 0 to 30 in our study. In CV, given α 1 , α 2 or α, we can obtainμ * ik . Then we calculatê
is the 100(1 − θ)th percentile of {μ * i , i = 1, . . . , p}, we let λ =μ *
and use it to shrink. Similarly, for group shrinkage, we replaceμ * ik by ||μ * k || G j . The best combination of the shrinkage parameters were selected based on the smallest number of test errors. When there are two or more combinations giving the same smallest test error rates, to break ties, our strategy is to first use as a small number of genes as possible, which means to choose the smallest θ; if still tied, we choose the smallest α 1 to decrease the weight of the sample covariance matrix; if still tied, we choose the group independence over the individual independence by choosing largest α 2 or α.
Connection to penalized likelihoods
Let X be centered raw expression data, i.e. x ij = x raw ij −x raw j . Each gene expression sample is denoted by a p × 1 vector X i = (x i1 , . . . , x ip ) T and mean of class k is denoted by µ k = (µ k1 , . . . , µ kp ) T . In LDA, µ k and Σ are estimated by MLEs. In this section, we show the connections between our method and penalized log-likelihood methods; for derivations, see Tai and Pan (2007b) . The penalized log-likelihood can be expressed as
where
is a multivariate normal log-likelihood and P λ (µ k , Σ) is a penalty function for parameters µ and Σ. (2006) and Wang and Zhu (2007) ,
PAM As pointed out by Wu
, and use an L 1 norm penalty
P p j=1 n k |µ kj | on µ k , the nearest shrunken centroids estimators are the maximizer of L λ with X i replaced by Z i .
GSCGRDA
For GSCGRDA, we assume a between-group independence covariance matrix Σ = diag(Σ 1 , . . . , Σ G ), where Σg is the covariance for group g (g = 1, . . . , G). Accordingly, we apply a group penalty on µ k (Yuan and Lin, 2006) , resulting in the following penalized log-likelihood
where ||µ kg || = q P l∈Gg µ 2 kl is the L 2 norm of mean vector and pg is the group size for group g. It can be shown that a sufficient and necessary condition for µ k to be a maximizer of (7) is
and
wherex kg is a pg × 1 vector whose elements are average gene expressions over class k for each gene that belongs to group g. Equation (8) is a nonlinear system and has no closed-form solution. In GSCGRDA, we usê
as an approximate solution to (8). If
or in other words, if x kg is an eigenvector of Σg, then solution (10) becomes exact for (8).
The covariance matrix estimatorΣ = αΣ * + (1 − α)D used in GSCGRDA can be regarded as a maximizer of penalized likelihood
with µ k estimated byx k , and D = diag (D 1 , . .., D G ) and Σ = diag(Σ 1 , ..., Σ G ). The penalty term tr(DgΣ −1 g ) corresponds to prior distribution of Σg as an inverse Wishart distribution with mean Dg. A similar idea of derivingΣ in (2) as an empirical Bayes estimator was discussed by Srivastava and Kubokawa (2007) . In this paper we use D =D.
Computational issues
With high-dimensional microarray data it takes too much memory space or even infeasible to invert a p × p covariance matrix, where p is in the order of thousands or tens of thousands. In order to efficiently and stably invert such a large and potentially sparse matrix, we use the Woodbury formula so that the memory requirement is reduced from inverting a p × p matrix to an n × n matrix; the latter is quite small for microarray data with n less than hundreds. The Woodbury formula can be expressed as
For simplicity of the discussion, we replaceD with I in formulas (4) and
Hence, if we have A −1 , we can calculateΣ by applying the Woodbury formula. Notice that A = α 2Σ * +(1−α 1 −α 2 )I is a block diagonal matrix with each block denoted as A i and
we invert it by the Cholesky decomposition; otherwise, we apply the Woodbury formula to A i ,
In this way, the largest matrix we need to invert is the n × n matrix In + bX i X i , which is computationally affordable, considering n is usually small in microarray data analysis. In the context of discriminant analysis, our final goal is to compute the discriminant score δ k (x). If we can obtaiñ Σ −1 µ k , which is p × K, then we can compute the discriminant scores for classification.
Thus we only need to store A −1 X and A −1 µ k , instead ofΣ −1 . The above computational strategy proves to be efficient and robust in practice.
RESULTS
Simulation
For evaluation, we compared our methods to PAM and SCRDA on simulated data. As discussed above, the major difference between these methods is the assumption on the form of the covariance matrix. Hence we considered simulation set-ups with four different covariance matrices. For each simulated dataset in each case, we had two classes and p = 1000 variables; there were 50 training samples and 500 test samples for each class; the small training samples reflected typical microarray data sizes while the large test samples were used for obtaining accurate test error rates for the purpose of evaluations only. Gene expression levels X were generated from two multivariate normal distributions with different mean vectors but the same covariance structure. Specifically,
µ1 and µ2 were p × 1 vector. All the elements in µ1 were 0. The first 100 elements in µ2 were randomly drawn from uniform (0,1), µ2,1, . . . , µ2,100 ∼ U (0, 1) and the remaining ones were 0. The choices of covariance matrices were respectively 1. an identity matrix; 2. a compound symmetric (CS) matrix with ρ = 0.2: the correlation between any two genes was ρ;
3. a block diagonal matrix with each block as CS: the block size was 50×50, resulting in a total of 20 blocks. The within-blockwise correlations were ρ1, . . . , ρ20 ∼ U (0, 1)
4. a block diagonal matrix plus a weak CS correlation for other off-block elements: the blocking structure was the same as in case 3 with the within-block correlations ρ1, . . . , ρ20 ∼ U (0.5, 1), and the correlation for off-block elements was ρ ∼ U (0, 0.1)
For the purpose of comparison, we also included results for a weighted PAM (wPAM) method (Tai and Pan 2007) and support vector machines (SVM) (Vapnik 1998 ). The wPAM is a modification to PAM with multiple shrinkage parameters to accommodate gene groups. We used binary SVMs implemented in the svm function in R package e1071; we used the default radial kernel; for each simulated dataset, ten-fold CV was used to select two tuning parameters, the gamma (a parameter with the radial kernel) and the cost parameter C; both parameters were searched on a grid (10 −5 , 10 −4 , ..., 10 4 , 10 5 ); because the SVM results were added in the revision, the generated datasets might be different from the ones used for other methods, but we do not expect that the conclusion would change otherwise. Note that SVM was very slow while could not conduct variable selection.
For the grouped methods, we grouped variables according to the blocking structure in case 3 and used this grouping scheme throughout all four simulation set-ups when applying any groupbased method. More specifically, we grouped 1000 variables into 20 groups with 50 variables in each group, the first 50 variables in group one, the next 50 variables in group two, etc.
To investigate the robustness of the proposed methods to group misspecification, we also considered three scenarios:
• Mixed groups (mix). We randomly chose m ∼ U (0, 40) genes from each group, then randomly reassigned them to one of the 20 groups; in this way, about 40% genes' groups were misspecified.
• New groups (new). We randomly chose m ∼ U (0, 40) genes from each group, and then treated them as separate groups.
• Divided groups (div). We randomly divided each of 4 groups (1 informative and 3 noninformative ones) into 2 groups of nearly equal size.
The results are summarized in Table 1 . As expected, in general, the method with the correct assumption on the underlying covariance matrix outperformed other methods with incorrect assumptions. There was no big difference among all the methods for the true independence model, perhaps due to the RDA-based methods' flexibility of including the independence model as a special case; surprisingly, GSCGRDA performed even slightly better than PAM. Albeit not really practical for microarray data, the CS case was most suitable for SCRDA, which outperformed other methods; though ISCGRDA-1 had the flexibility of modeling any general covariance structure, it performed slightly worse than SCRDA due to the cost of former's estimating one more tuning parameter in its regularized covariance estimator. The block diagonal-CS model was ideal for the group-based RDA methods, which outperformed SCRDA, PAM and wPAM by significant margins; GSCGRDA performed best in this cases. For the block diagonal CS plus a weak off-block CS case, which was perhaps most representative for real microarray data with stronger within-group correlations and weaker between-group correlations, GSCGRDA was a clear winner, followed by our other two proposed methods; the three new methods, even under largely misspecified groups, performed much better than PAM and SCRDA. In general, the new methods were robust to group mis-specifications. PAM and wPAM performed pretty well under the independence case, but suffered severely for other cases because of their ignoring existing correlations. SCRDA performed well in general for all cases, especially when correlations among the genes were fairly strong, but it tended to use more genes than other methods probably because it was unable to capture the sparseness of an underlying covariance matrix. ISCGRDA-1 performed well in all cases due to its generality. However, it suffered from its high computational cost. ISCGRDA-2 performed similarly to ISCGRDA-1 except for the CS case. In terms of prediction error, GSCGRDA outperformed all the other methods except in the CS case, in which it was ranked the second only behind SCRDA. For variable selection, it selected a much higher proportion of informative genes while eliminating much more noise genes. In addition, by using a block covariance structure along with the group shrinkage, GSCGRDA had the capability of genuine gene selection as compared to other RDA-based methods. In particular, GSCGRDA performed better than SVM, which was not really surprising because the former method (along with other LDA-type methods) used the normality assumption on the predictors.
Real Data
We also applied all methods to four public microarray gene expression datasets for tumor classifications.
1. Breast cancer data . There were in total n = 52 samples (18 with recurrence of tumor and 34 without). Each sample contained p = 12625 genes.
2. Lung cancer data (Gordon et al., 2002) . The goal was to discriminate between malignant pleural mesothelioma (MPM) and adenocarcinoma (ADCA) of the lung. There were n = 181 tissue samples (31 MPM and 150 ADCA). Each sample contained p = 12533 genes. 3. Prostate cancer data (Singh et al., 2002) . The goal was to classify between 77 tumor samples and 59 normal samples. Each sample contained p = 12600 genes.
4. Leukemia data (Armstrong et al., 2001) . The goal was to classify each of 62 leukemia samples (24 ALL, 20 MLL and 28 AML) into one of the three subtypes. There were p = 12582 genes.
Gene groups were formed based on the KEGG pathways (Kanehisa 1996) : the genes in a KEGG pathway formed a group, while each of the genes that was not annotated in any KEGG pathway formed its own group with group size one. To deal with the genes annotated in multiple pathways, we applied two methods: 1.(the default): we kept a gene to the pathway with the smallest ID while ignoring its belonging to other pathways; 2. (Dup): we duplicated the expression profile of the gene in each pathway to which it belonged to.
As a pre-screening, we only used various subsets of the genes in each dataset: we used the genes in KEGG pathways along with the top 3000 genes with the largest sample variances. Results in Table 2 were based on ten independent repeats of 10-fold CV; within each CV, a second-level CV was used to select tuning parameters. The RDA-based methods tended to use more genes than PAM or wPAM; in particular, SCRDA used almost all the genes for each dataset. However, RDA-based methods performed significantly better than PAM and wPAM for the prostate cancer data. The GSC-GRDA performed consistently well for all datasets: it was the best for the breast cancer data and leukemia data, the second best for the prostate cancer data and performed closely to the winner (wPAM) for the lung cancer data. It also consistently outperformed other two GRDA-based methods. In addition, the genes selected from GSC-GRDA had a biological interpretation: any group of more than one genes selected at the end corresponded to a KEGG pathway. In Table  3 , we show the top 10 most frequently selected pathways by GSC-GRDA based on 100 models from 10 repeats of 10-fold CV. Since GSCGRDA selected almost all of the genes for the prostate cancer data, we do not list the selected pathways for the data. It was somewhat reassuring that the two treatments of the genes with multiple annotations in GSCGRDA gave almost equal performance in terms of misclassifications, while the duplication method seemed to select an almost equal number of or fewer unique genes as compared to the first treatment; more work is needed on how to handle the genes with multiple annotations for grouped methods.
To empirically verify the "stronger within-group and weaker between-group correlations" assumption, based on the lung cancer data, we calculated pairwise Pearson's correlations among the genes within three pathways (with IDs 04514, 04020 and 04360) and the collection of all other genes not in any pathway. For the three pathways, the median correlations were 0.092, 0.095 and 0.097, and the 75th percentiles were 0.169, 0.167, 0.168 respectively, larger than 0.090 and 0.159 for the non-annotated genes.
DISCUSSION
In this article, we have proposed a class of modified LDA to incorporate prior knowledge on gene functions into building a classifier. A main difference from other modifications of LDA is that we regularize the covariance matrix by considering group relationships among variables. Unlike most standard classifiers, which treat all the genes equally a priori, our methods assume that the genes in the same group are more likely to function similarly and thus have correlated expressions while the genes from different functional groups or pathways are more likely to be independent or only weakly correlated. We introduce a between-group independence (i.e. block-diagonal) covariance structure into regularization and put more weight on it to account for the biological belief of higher within-group but lower between-group gene correlations. Another main difference is our consideration of a group shrinkage scheme that tends to retain or remove a whole group of the genes altogether. When gene groups are formed informatively, it may not only improve predictive performance, but also facilitate interpretation of results. Although the genes within such selected pathways may be useful for the purpose of clinical outcome classifications, we cannot determine whether differential expressions of these genes are the cause or only manifestation of different outcomes; in fact, even for the purpose of diagnosis or prognosis, more studies may be still needed to evaluate whether identified genes are really trustworthy predictors.
Among the methods studied, in general, GSCGRDA performed best for our simulated and real data. In addition, an advantage of GSCGRDA over other RDA-based methods is that it can realize gene selection while the others cannot. In particular, gene selection is accomplished at the group level, thus naturally associating selected gene groups to their biological interpretations, e.g. pathways.
Furthermore, compared to ISGRDA-1 and SCRDA, GSCGRDA is much less computationally intensive by excluding the use of the unrestrictive sample covariance estimate.
Although we only used the KEGG pathways to form gene groups in the real data examples, other sources of biological knowledge for gene functions or pathways, such as GO, can be also utilized in our proposed methods. However, how to take advantage of the hierarchical structure of GO annotations, or known or predicted gene networks, is unclear. Furthermore, how to handle genes with multiple annotations warrants more research. Finally, it may be productive to combine the idea proposed here with other improved PAM methods (Wang and Zhu 2007) . These are interesting topics to be studied.
